|
|
|
|
|
|
European governments navigate an ever more competitive global landscape, stagnating productivity and competing demands on budgets. We have successfully faced and solved many challenges in the past, but this situation is different: the choices we make today will shape our health care systems and patient care, and these choices will dictate Europe’s economic performance and global relevance for decades to come.
|
|||||
|
|
New research for EFPIA by Charles River Associates provides the first comprehensive overview of the EU’s attractiveness as a destination for pharmaceutical investment, benchmarked against its global competitors: US, China, UK and Switzerland.
While Europe retains important strengths, other regions have rolled out ambitious strategies to attract investment, innovation and talent.
How can Europe keep pace?
|
|
|
On 17 March, we were pleased to take part in the Euractiv hybrid conference “Improving Europe’s Water Quality: How can the revised UWWTD be implemented fairly and effectively?” As Nathalie Moll, EFPIA Director General, highlighted, “we all share the same objective of having clean water in Europe,” while stressing the need for “a fair share of the cost among all the polluters present in the water,” based on transparent, science-based data to ensure the right balance between environmental goals, patient access to medicines, and Europe’s competitiveness. Watch the recording here. |
|
|
|
J&J | The essentials of partnering with a pharma company
Utrecht & Virtual
Discover what it takes to build successful collaborations with pharmaceutical companies and accelerate your innovation... Learn more → |
|||
|
|
POLITICO Competitive Europe Summit 2026
Brussels, Belgium
Caught between geopolitical turmoil, mounting pressure to deliver growth and war raging at its doorstep, the EU stands... Learn more → |
|||
|
|
DIA Europe 2026
Rotterdam, Netherlands
Join the DIA Europe 2026 in March to explore how Europe can bring and keep innovation into the system to deliver better... Learn more → |
|||
|
|
Europe’s Choice: Investing in sustainable health systems
Brussels, Belgium
At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening,... Learn more → |
|||
|
|
New PRIME tools to accelerate development of medicines in the EU
18 March 2026 (European Medicines Agency)
EMA launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines...
|
|
Respiratory infections and long-term illness: a two-way street
18 March 2026 (Vaccines Today)
Until recently, long-term conditions (such as diabetes, obesity, cardiovascular disease and cancer) were seen as...
|
|
Fostering greater collaboration in rare disease research
16 March 2026 (Rare Revolution Magazine)
Collaboration lies at the heart of rare disease research because its unique challenges can only be overcome by working...
|
|
|||
|
|||||
|
EFPIA 2026 All rights reserved ·
Disclaimer
·
|